To announce that 2022Q2 Consolidated Financial
Statement approved by the Board of Directors
Date of events
2022/08/03
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/08/03
2.Date of the audit committee approved:2022/08/03
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):273,994
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):107,237
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):9,688
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):15,136
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):11,768
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):11,599
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):0.48
11.Total assets end of the period (thousand NTD):441,698
12.Total liabilities end of the period
(thousand NTD):117,406
13.Equity attributable to owners of parent end of the
period (thousand NTD):324,343
14.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Genetics Generation Advancement Corporation published this content on 03 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 August 2022 08:25:03 UTC.
Genetics Generation Advancement Corp is a Taiwan-based company principally engaged in genetic testing business. The Company mainly provides genetic testing, molecular diagnostics, biotechnology, personalized medical related testing, biological information and health care services. The Company mainly serves in the areas of maternal-fetal precision, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection and precision health management. The Company operates its businesses in domestic market and overseas markets.